Idorsia Ltd (IDIA.SW)
CHF 1.3
(2.45%)
CHF 1.3
(2.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -543.05 Million CHF | 32.37% |
| 2022 | -802.96 Million CHF | -30.99% |
| 2021 | -613 Million CHF | -49.3% |
| 2020 | -410.58 Million CHF | 14.89% |
| 2019 | -482.42 Million CHF | -30.01% |
| 2018 | -371.07 Million CHF | -4606.68% |
| 2017 | -7.88 Million CHF | 97.56% |
| 2016 | -322.81 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -92 Million CHF | 18.49% |
| 2024 Q1 | -94.61 Million CHF | 17.45% |
| 2024 Q2 | -97.05 Million CHF | -2.58% |
| 2023 Q3 | 230.8 Million CHF | 230.39% |
| 2023 FY | -543.05 Million CHF | 32.37% |
| 2023 Q1 | -197.58 Million CHF | -4.03% |
| 2023 Q2 | -177 Million CHF | 10.42% |
| 2023 Q4 | -114.6 Million CHF | -149.66% |
| 2022 Q3 | -208.4 Million CHF | 1.74% |
| 2022 FY | -802.96 Million CHF | -30.99% |
| 2022 Q4 | -189.92 Million CHF | 8.87% |
| 2022 Q2 | -212.08 Million CHF | -10.15% |
| 2022 Q1 | -192.54 Million CHF | 15.67% |
| 2021 FY | -613 Million CHF | -49.3% |
| 2021 Q4 | -228.32 Million CHF | -71.5% |
| 2021 Q3 | -133.13 Million CHF | -2.61% |
| 2021 Q2 | -129.74 Million CHF | -6.53% |
| 2021 Q1 | -121.79 Million CHF | 0.62% |
| 2020 FY | -410.58 Million CHF | 14.89% |
| 2020 Q3 | -109.84 Million CHF | -63.52% |
| 2020 Q1 | -111 Million CHF | 12.64% |
| 2020 Q2 | -67.17 Million CHF | 39.48% |
| 2020 Q4 | -122.55 Million CHF | -11.57% |
| 2019 Q2 | -120.57 Million CHF | -1.57% |
| 2019 Q1 | -118.72 Million CHF | -18.11% |
| 2019 FY | -482.42 Million CHF | -30.01% |
| 2019 Q4 | -127.06 Million CHF | -9.49% |
| 2019 Q3 | -116.05 Million CHF | 3.75% |
| 2018 Q3 | -115.23 Million CHF | -42.46% |
| 2018 Q1 | -74.42 Million CHF | -205.55% |
| 2018 FY | -371.07 Million CHF | -4606.68% |
| 2018 Q4 | -100.51 Million CHF | 12.77% |
| 2018 Q2 | -80.89 Million CHF | -8.68% |
| 2017 FY | -7.88 Million CHF | 97.56% |
| 2017 Q1 | -111.52 Million CHF | 0.0% |
| 2017 Q2 | 100.93 Million CHF | 190.51% |
| 2017 Q4 | 70.51 Million CHF | 203.17% |
| 2017 Q3 | -68.35 Million CHF | -167.72% |
| 2016 FY | -322.81 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -5166.633% |
| BB Biotech AG | -29.92 Million CHF | -1714.528% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 2927.659% |
| Evolva Holding SA | -92.24 Million CHF | -488.704% |
| Kuros Biosciences AG | -13.19 Million CHF | -4016.525% |
| Molecular Partners AG | -61.1 Million CHF | -788.676% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | -389.995% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 888.815% |